Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14847734 | 0.83 | PAX8 (0.47) | SMN1; SMN2ALOX15HTTHPGDKMT2A | |
| SCHEMBL3372477 | 0.74 | HDAC1 (0.58) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL3608521 | 0.73 | HDAC6 (0.54) | HTTHPGDRAB9A | |
| SCHEMBL371155 | 0.70 | UBE2T (0.63) | SMN1; SMN2ALOX15HTTHPGDKMT2A | |
| SCHEMBL14833539 | 0.70 | HDAC6 (0.52) | SMN1; SMN2KMT2ARAB9AGAAALDH1A1 | |
| SCHEMBL29726344 | 0.70 | GAA (0.55) | SMN1; SMN2ALOX15HTTHPGDKMT2A | |
| SCHEMBL1612659 | 0.70 | SMN1; SMN2 (0.67) | SMN1; SMN2ALOX15HTTHPGDKMT2A | |
| SCHEMBL5722086 | 0.69 | HDAC1 (0.53) | KMT2AMEN1LMNAKDM4ETSHR | |
| SCHEMBL5722085 | 0.69 | HDAC1 (0.53) | KMT2AMEN1LMNAKDM4ETSHR | |
| SCHEMBL6028429 | 0.69 | KMT2A (0.56) | SMN1; SMN2ALOX15HTTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760845-B1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9376425-B2 | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| EP-2760845-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049250-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | SMN1; SMN2 2972/4885ALOX15 2706/4885HTT 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.